Incyte Announces New Long-Term Data From Phase 3 TRuE-V Program Demonstrates Efficacy Of Continued Treatment With Opzelura Cream In Nonsegmental Vitiligo Patients
Portfolio Pulse from Benzinga Newsdesk
Incyte (NASDAQ:INCY) has announced new results from its Phase 3 TRuE-V program, demonstrating the efficacy of continued treatment with Opzelura cream in nonsegmental vitiligo patients. The data shows that patients who initially experienced limited or no facial or total body repigmentation at six months achieved improved repigmentation after continued treatment with Opzelura for up to two years. The treatment was well-tolerated with no serious treatment-related adverse events reported.
October 11, 2023 | 2:32 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Incyte's new data from its Phase 3 TRuE-V program shows the efficacy of Opzelura cream in treating nonsegmental vitiligo patients. This could potentially increase the demand for Opzelura, positively impacting Incyte's revenues.
The new data from Incyte's Phase 3 TRuE-V program demonstrates the efficacy of Opzelura cream in treating nonsegmental vitiligo patients. This positive result could potentially increase the demand for Opzelura, leading to increased revenues for Incyte. Therefore, the impact on Incyte's stock is likely to be positive in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100